Serdexmethylphenidate is part of the composition of Azstarys, which consists of a
prodrug/drug co-formulation ofserdexmethylphenidate and
dexmethylphenidate in a 70:30 molar ratio. Azstarys is approved by the USFDA for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older.
Serdexmethylphenidate consists of pharmacologically active dimethylphenidate attached to the nicotinoyl-L-serine portion via a carboxymethylene linker.
Catabolism of serdexmethylphenidate is believed to occur
in the lower gastrointestinal tract. As a result, therapeutic doses
of the released dexmethylphenidate do not generally appear
until several hours after ingestion. As such, the long-duration
action of this prodrug is combined with immediate-release
dexmethylphenidate in the marketed combination therapy.
